MediWound Ltd.
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The company specializes in the development, production, and commercialization of rapid and effective biologics that enhance existing standards of care, improve patient experiences, and reduce costs and unnecessary surgeries.
Industries
Nr. of Employees
medium (51-250)
MediWound Ltd.
42 Hayarkon Street, Yavne 8122745, Israel
Awards
Far-Forward Burn Treatment
Development of NexoBrid as a non-surgical debriding Solution for Far Forward Burn Treatment (FFBT)
Funding (ceiling)
$17,053,903.94
Award Year
2021
Patents
Proteolytic extract from bromelain for the treatment of connective tissue disorders
2019-05-21 • US-10293033-B2
View DetailsProteolytic extract from bromelain for the treatment of connective tissue disorders
2016-12-06 • US-9511126-B2
View DetailsDebriding composition from bromelain and methods of production thereof
2013-09-24 • US-8540983-B2
View DetailsDebriding composition from bromelain and methods of production thereof
2012-02-21 • US-8119124-B2
View Details
Proteolytic extract from bromelain for the treatment of connective tissue disorders
2019-05-21 • US-10293033-B2
View DetailsProteolytic extract from bromelain for the treatment of connective tissue disorders
2016-12-06 • US-9511126-B2
View DetailsDebriding composition from bromelain and methods of production thereof
2013-09-24 • US-8540983-B2
View DetailsDebriding composition from bromelain and methods of production thereof
2012-02-21 • US-8119124-B2
View DetailsProducts
NexoBrid
Topically administered concentrate of proteolytic enzymes for selective removal of burn eschar in deep partial‑ and full‑thickness thermal burns; authorized in multiple jurisdictions including the U.S., EU and Japan.
EscharEx
Topical concentrate of proteolytic enzymes in clinical development for debridement of chronic and hard‑to‑heal wounds (e.g., venous leg ulcers, diabetic foot ulcers); demonstrated safety and efficacy in Phase II studies and advancing to Phase III.
MW005
Topical proteolytic enzyme‑based biologic candidate developed for non‑surgical treatment of low‑risk basal cell carcinoma; early clinical data indicate safety and lesion clearance in initial cohorts.
NexoBrid
Topically administered concentrate of proteolytic enzymes for selective removal of burn eschar in deep partial‑ and full‑thickness thermal burns; authorized in multiple jurisdictions including the U.S., EU and Japan.
EscharEx
Topical concentrate of proteolytic enzymes in clinical development for debridement of chronic and hard‑to‑heal wounds (e.g., venous leg ulcers, diabetic foot ulcers); demonstrated safety and efficacy in Phase II studies and advancing to Phase III.
MW005
Topical proteolytic enzyme‑based biologic candidate developed for non‑surgical treatment of low‑risk basal cell carcinoma; early clinical data indicate safety and lesion clearance in initial cohorts.
Expertise Areas
- Enzymatic therapeutics development
- Topical biologic formulation and CMC development
- Clinical trial management for wound, burn and dermatology indications
- Preclinical wound model development (including porcine models and in vitro biofilm assays)
Key Technologies
- Proteolytic enzyme enrichment platform (plant-derived)
- Topical biologic formulation technologies
- Proteolytic debridement mechanism-of-action
- Preclinical porcine wound models
Key People
News & Updates
MediWound Ltd. announced that the Company will release its financial results for the third quarter ended September 30, 2022 on November 15, 2022.
MediWound Ltd. announced the establishment of a Strategic Advisory Board (SAB) to guide the Company with experienced executives.
Positive clinical data from the Company’s EscharEx® Phase 2 trials was featured in presentations at the SAWC Fall 2022 Conference.
The U.S. FDA has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound announced it has gained marketing approval of NexoBrid® in India, with plans for commercialization in the first half of 2023.
MediWound Ltd. announced that the Company will release its financial results for the third quarter ended September 30, 2022 on November 15, 2022.
MediWound Ltd. announced the establishment of a Strategic Advisory Board (SAB) to guide the Company with experienced executives.
Positive clinical data from the Company’s EscharEx® Phase 2 trials was featured in presentations at the SAWC Fall 2022 Conference.
The U.S. FDA has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound announced it has gained marketing approval of NexoBrid® in India, with plans for commercialization in the first half of 2023.